|Anti-hPD-L1-hIgG1 (N298A)||Unit size||Cat. code||Docs||Qty||Price|
Human PD-L1 (atezolizumab) antibody - Human IgG1 (N298A)
Anti-hPD-L1-hIgG1 (N298A) features the constant region of the human IgG1 (N298A) isotype and the variable region of atezolizumab. Atezolizumab (also known as MPDL3280A) is a fully humanized IgG1 (N298A) monoclonal antibody that targets the programmed cell death ligand 1 (PD-L1), a transmembrane protein over-expressed on tumor cells and tumor infiltrating immune cells, such as macrophages. PD-L1 binds to programmed cell death protein 1 (PD-1) on cytotoxic T cells, inhibiting the antitumor immune response . Atezolizumab blocks the interaction of PD-L1 with PD-1 and induces anti-tumor immune reactivation. This mAb contains a modified Fc region designed to limit antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [2, 3]. The mutation N298A eliminates its ability to bind to human Fcγ receptors. FDA has granted atezolizumab priority review for advanced bladder cancer.
Anti-hPD-L1-hIgG1 (N298A) was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.
1. McDermott D. & Atkins M. 2013. PD-1 as a potential target in cancer therapy. Cancer Med. 2(5): 662–673.
2. Spigel D. et al., 2013. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [ASCO abstract 8008]. J Clin Oncol. 31(15)(suppl).
3. Herbst RS. et al., 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515(7528):563-7.
Specificity: Targets cells expressing human and mouse PD-L1
Clonality: Monoclonal antibody
Isotype: Human IgG1 (N298A)
Source: CHO cells
Purity: Purified by affinity chromatography with protein G
• 100 µg purified anti-hPD-L1-hIgG1 (N298A) antibody, provided azide-free and lyophilizedBack to the top